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The Mycobacterium tuberculosis H37Rv genome encodes 20
cytochromesP450, includingP450s crucial to infection andbac-
terial viability. Many M. tuberculosis P450s remain uncharac-
terized, suggesting that their further analysis may provide new
insights into M. tuberculosis metabolic processes and new tar-
gets for drug discovery. CYP126A1 is representative of a P450
family widely distributed in mycobacteria and other bacteria.
Here we explore the biochemical and structural properties
of CYP126A1, including its interactions with new chemical
ligands. A survey of azole antifungal drugs showed that
CYP126A1 is inhibited strongly by azoles containing an imidaz-
ole ring but not by those tested containing a triazole ring. To
further explore the molecular preferences of CYP126A1 and
search for probes of enzyme function, we conducted a high
throughput screen. Compounds containing three or more ring
structures dominated the screening hits, including nitroaro-
matic compounds that induce substrate-like shifts in the heme
spectrumofCYP126A1. Spectroelectrochemicalmeasurements
revealed a 155-mV increase in heme iron potential when bound
to one of the newly identified nitroaromatic drugs. CYP126A1
dimers were observed in crystal structures of ligand-free
CYP126A1 and for CYP126A1 bound to compounds discovered
in the screen. However, ketoconazole binds in an orientation
that disrupts the BC-loop regions at the P450 dimer interface
and results in a CYP126A1 monomeric crystal form. Structural
data also reveal that nitroaromatic ligands “moonlight” as sub-
strates by displacing the CYP126A1 distal water but inhibit
enzyme activity. The relatively polar active site of CYP126A1
distinguishes it from its most closely related sterol-binding
P450s inM. tuberculosis, suggesting that further investigations
will reveal its diverse substrate selectivity.
The human pathogenMycobacterium tuberculosis remains a
major global cause of mortality as the infectious bacterium that
causes tuberculosis (TB)8 (1). Recent data from the World
Health Organization indicate that TB is the leading cause of
human death worldwide among infectious diseases (2). The
mortality rate in TB victims may be increased by co-infection
with the human immunodeficiency virus (HIV). Moreover, the
development of M. tuberculosis strains resistant to leading
drugs usually results in extended treatment times (2). Multi-
drug-resistant (MDR) and extensively drug-resistantM. tuber-
culosis strains are resistant to at least the two leading TB drugs
(rifampicin and isoniazid) or to both of these drugs as well as to
any one of the quinolone drugs and to at least one of the second-
line injectable TB drugs amikacin, capreomycin, and kanamy-
cin (3, 4). Consequently, there is increased need for develop-
ment of new TB drugs with novel modes of action. This need
has been partially met recently by the development of drugs
such as delamanid (which inhibits cell wallmycolic acid synthe-
sis) and bedaquiline (an M. tuberculosis ATPase proton pump
inhibitor), both of which have been authorized for use in MDR
TB treatment (5).
A revelation from the first genome sequence of M. tubercu-
losis (that for the virulent H37Rv strain) was that 20 different
cytochrome P450 (CYP or P450) enzymes were encoded (1).
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This large number of P450s suggested important functions for
these enzymes, and key roles for M. tuberculosis P450s were
identified in the metabolism of host cholesterol/cholest-4-en-
3-one (CYP125A1 and CYP142A1) and branched chain lipids
(CYP124A1), oxidative tailoring of cyclic dipeptides (CYP121A1),
hydroxylation of menaquinone (CYP128A1), and sterol de-
methylation (CYP51B1) (6–14). The CYP125A1 and CYP142A1
genes are located in a gene regulon associated with host choles-
terol metabolism and uptake and are required for oxidative
metabolism of the steroid side chain to initiate its catabolism by
M. tuberculosis in the macrophage (7, 8, 15). CYP128A1 is
implicated in the synthesis of a virulence-associated sulfolipid
(S881) through hydroxylating menaquinone 9, (MK9H2), the
sole quinol electron carrier in the M. tuberculosis respiratory
chain. CYP128A1 catalyzes terminal hydroxylation of MK9H2
to enable sulfation at the hydroxyl group by the sulfotransferase
Stf3 encoded by the gene Rv2267c, immediately downstream of
CYP128A1 (1, 12).
The first M. tuberculosis P450 to be structurally and bio-
chemically characterizedwasCYP51B1, the firstmember of the
CYP51 (sterol demethylase) gene family identified in a pro-
karyote (13, 16, 17). The CYP51B1 FeII-CO complex is unstable
and collapses from the cysteine thiolate-coordinated P450 form
to the thiol-coordinated P420 state. However, the thiolate-
coordinated form is stabilized by binding of estriol (14). Later
studies on theM. tuberculosis cholesterol hydroxylase CYP142A1
and the Sorangium cellulosum epothilone C/D epoxidase EpoK
showed that binding of substrates (cholest-4-en-3-one and
epothilone D, respectively) regenerated the P450 state when
added to the FeII-CO P420 forms (8, 18). Importantly, the sol-
uble CYP51B1 enzyme catalyzes oxidative 14-demethylation
of lanosterol, 24,25-dihydrolanosterol, and the plant sterol
obtusifoliol and also binds azole drugs used clinically to inhib-
it fungal CYP51 enzymes (13, 17). These findings inspired
research to examine the potency of azole drugs against myco-
bacteria. In vitro studies revealed that several azoles had good
MIC values against Mycobacterium smegmatis, particularly
econazole (0.1g/ml) andmiconazole (0.1g/ml). The same
two azoles were also the most effective againstM. tuberculosis
H37Rv, albeit with higher MIC values (8 g/ml for both drugs)
(19, 20). This is possibly due to lower azole penetration into
M. tuberculosis cells or to drug efflux (21). Studies in mice also
showed that econazole reduced bacterial burden by 90% in
lungs and spleen and was also effective against MDR
M. tuberculosis strains (22, 23). Thus, regardless of issues
surrounding cross-reactivity of azole drugs with human
P450s, various azoles are clearly potent inhibitors of
M. tuberculosis P450s and are important tools for character-
ization of these enzymes (13, 24).
Several of the M. tuberculosis P450s remain structurally
uncharacterized. Among these is CYP126A1, a P450 with
35% amino acid identity to the cholesterol-oxidizing
M. tuberculosis CYP142A1 and CYP125A1. The CYP126A1
(Rv0778) gene is located in a region close to genes encoding the
sterol demethylase P450 CYP51B1 (Rv0764c) and the unchar-
acterized CYP123A1 (Rv0766c), an enzyme that is predicted to
be associatedwith theM. tuberculosisH37Rv cellmembrane by
2D LC-MS analysis (25). CYP126A1 is also located between
genes involved in purine synthesis (purB, Rv0777; purC,
Rv0780; and purD, Rv0772), although there is no evidence for
its involvement in this pathway. However, CYP126A1 is highly
conserved across pathogenic and non-pathogenic Mycobacte-
rium species, suggesting an important evolutionary role for the
protein.
In previous studies, we have taken a fragment-based
approach to identify novel small molecule ligands forM. tuber-
culosis P450s, including CYP121A1, CYP125A1, and CYP126A1
(26–28). In this paper, we present detailed biochemical, spec-
troscopic, and structural data for CYP126A1, including studies
of its binding to novel substrates and inhibitors identified from
a library of 40,000 compounds structurally related to the
World Drug Index (29). The crystal structures of CYP126A1 in
complex with the azole drug ketoconazole and with inhibitor
and substrate-like molecules from the screen are presented,
illustrating the capacity of CYP126A1 to bind bulky com-
poundswith several rings. NativeCYP126A1was found to form
a crystallographic dimer in which both open and closed forms
of the protein (with respect to P450 conformation and active
site access) are observed. In contrast, the CYP126A1-ketocona-
zole structure is a crystallographic monomer. These data pro-
vide important insights into the structural properties and the
molecular selectivity of thisM. tuberculosisP450 enzyme, high-
lighting its capacity to bind large compounds, and the ability of
molecules with nitroaromatic groups to “moonlight” as sub-
strates through inducing formation of high spin (HS) heme
iron in CYP126A1. This is the first report of structural data
for the widely conserved M. tuberculosis CYP126A1 P450
enzyme and provides important insights into CYP126A1
molecular selectivity and structural adaptation to the bind-
ing of large compounds.
Results
Expression and Purification of CYP126A1—CYP126A1 was
purified from Escherichia coli expression cell extracts using Ni-
IDA chromatography followed by ion exchange chromatogra-
phy using Q-Sepharose. Using the Reinheitszahl (Rz) (A418/
A280) value as a guide to CYP126A1 protein purity, it was found
that a typical Ni-IDA step resulted in an45–50-fold purifica-
tion, with a further 3–4-fold purification achieved using
Q-Sepharose ion exchange chromatography. At this stage,
CYP126A1 was analyzed by SDS-PAGE and found to be highly
purified, with an apparent molecular mass of47 kDa (Fig. 1A,
inset). For protein destined for crystallography and P450
structural studies, either a second Q-Sepharose purification
step under the same conditions or a gel filtration step using
Sephacryl S-200 size exclusion chromatography (both on an
AKTA purifier) was used to ensure near homogeneity of the
CYP126A1 sample.
MS analysis of purifiedCYP126A1produced amass of 47,986
Da, which is consistent with that predicted for the His6-tagged
form of the heme-free apoprotein, after removal of the N-ter-
minal methionine (calculated mass  47,986.12 Da). A small
component with a mass of 48,601 Da is probably due to the
heme-bound form of CYP126A1 (calculated mass 48,602.62
Da) (Fig. 1A). Analysis of CYP126A1 by nano-electrospray ion-
ization (nano-ESI) native mass spectrometry revealed the
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enzyme to be predominantlymonomeric (Fig. 1B) at a relatively
low concentration (10M). Peaks in the regionm/z 3000–4200
were assigned to the CYP126A1monomer and were calculated
to have amass of 48,687 Da. A small amount of dimeric protein
was also present in the region m/z 4300–5300, with a mass of
97,352 Da. Analysis of CYP126A1 at a higher concentration (20
M) indicated a propensity for the protein to self-associate,
forming small amounts of trimeric (m/z 5300–6200, mass
14,6052Da) and tetrameric (m/z 6200–7300, mass 194,752Da)
oligomers, in addition to the CYP126A1 monomer and dimer.
Small deviations in masses probably arise from insufficient
evaporation of buffer components under the soft ionizing con-
ditions used (30).
UV-visible Spectroscopic Properties of CYP126A1 and Its
Complexes with Azole Drugs—The UV-visible spectrum of oxi-
dized (FeIII) CYP126A1 has major heme absorbance bands at
418.5 nm (Soret), 568.5 nm (), and 539 nm (). Reduction of
CYP126A1 with sodium dithionite results in a Soret band shift
to 412 nm with a Q-band feature at 544 nm. Binding of
carbon monoxide to reduced CYP126A1 results in a FeII-CO
complex with a Soret peak at 448.5 nm and a Q-band feature at
549 nm (Fig. 2). The spectral features of the ferrous and FeII-CO
forms of CYP126A1 are consistent with the retention of cys-
teine thiolate as the proximal ligand to the P450 heme iron.
However, the CYP126A1 FeII-CO complex converts slowly to
the cysteine thiol-coordinated P420 state (with Soretmaximum
at423 nm) after15 min, indicating a propensity for proto-
nation of the cysteine thiolate in this state, as is also seen in
other P450s, particularly in the absence of substrate (8, 18) (Fig.
2). Consistent with other M. tuberculosis P450s characterized
to date, CYP126A1 binds a range of antifungal compounds con-
taining imidazole heterocycles (7–10, 13, 14, 31) (Table 1).
These compounds all produced type II (red) shifts in the Soret
wavelength maximum (max) of the CYP126A1. For example,
ketoconazole induces a Soret shift from 418.5 to 423.5 nm at
apparent saturation, in addition to inducing smaller absor-
bance changes in the heme- and-bandpeaks (minor shifts to
569.5 and 540.5 nm, respectively, with notably decreased
intensity of the -band) (Fig. 3A). These spectral changes are
consistent with ligation of the heme iron by a heterocyclic
nitrogen atom. The CYP126A1 Kd for ketoconazole is 0.34 
0.07 M, whereas imidazole binds substantially more weakly
(Kd 2.59 0.06mM). A common feature in the spectral titra-
tions of CYP126A1 with imidazole group-containing azole
drugs (ketoconazole, miconazole, econazole, clotrimazole, and
imidazole itself) is the decrease in intensity of the red-shifted
Soret band by15–20% as the titration progresses to comple-
tion (Fig. 3A). The Kd values for the binding of these com-
pounds to CYP126A1 are given in Table 1 and compared with
previously reported values for their binding to otherM. tuber-
culosisP450s.None of the tested azole drugs containing triazole
groups (fluconazole, voriconazole, and itraconazole) gave any
convincing CYP126A1 Soret shifts, suggesting negligible or
very weak binding to this P450.
Identification of Novel CYP126A1 Ligands and Their Binding
Properties—To identify potential substrates and novel inhibi-
tors of CYP126A1, a high throughput compound screen was
undertaken. A series of ligands, compounds 1–9 (Fig. 4), were
FIGURE 1. Purification and mass spectrometry of CYP126A1. A, the main
image shows the native mass spectrum of CYP126A1. The major feature at
47,986 Da is consistent with the predictedmass of the His-tagged CYP126A1
apoprotein following removal of the initiator methionine (47,986.12 Da). The
minor feature (48,601 Da) is consistent with the mass for the heme-bound
CYP126A1 holoprotein. The inset shows an SDS-polyacrylamide gel with
molecular mass markers (sizes in kDa) in lane 1 and a sample of purified
CYP126A1 in lane 2. B, nano-ESI native mass spectra data of ligand-free
CYP126A1 at concentrations of 10M (top spectrum) and 20M (bottom spec-
trum). For the 10 M sample, differently charged species are labeled A (for
monomer) and B (for a minor dimer species). For the 20 M sample, species
are labeled A–D for the monomer through tetramer forms. Apparent masses
of these different species are indicated.
FIGURE 2. UV-visible spectral properties of CYP126A1. The ferric form of
CYP126A1 (6.5 M) has absorbance band maxima at 418.5 nm (Soret), 568.5
nm () and 539 nm () (thick solid line). Reduction with sodium dithionite
results in a Soret shift to412 nmwith aQ-band feature at544 nm (dashed
line). Binding of carbon monoxide results in a Soret shift to 448.5 nm with a
Q-band feature at549 nm (thin solid line), consistent with retention of cys-
teine thiolate coordination. Over a period of 10–15 min, this P450 form
converts to a P420 (thiol-coordinated) formwith a Soretmaximumat 423nm.
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selected using UV-visible spectroscopy on the basis of their
ability to induce either a substrate-like type I Soret shift (a blue
shift, indicative of conversion of the low spin (LS) CYP126A1
towardHS) or a type II Soret shift (a red shift, usually indicative
of heme iron coordination by a nitrogen or other atom from the
compound). Compounds 1–6 each produced type I CYP126A1
P450 spectra, with the Soret band shifting from 418.5 to395
nm. This is accompanied by a decrease in absorbance in the
/-band region from530–585 nm, and by increased absor-
bance at 650 nm characteristic for a cysteine thiolate-to-HS
ferric heme iron charge transfer (CT) complex. Fig. 3B shows a
spectral titration of CYP126A1 with compound 1, with data
fitted to give a Kd of 5.62 0.67 M. Compounds 1–6 contain
3–5 rings, and compounds 1 and 2 both have a nitro-aromatic
group at the end of the molecules. Affinity for compounds 1–6
varies in the range from 3 to 300 M (Table 2). Compounds
7–9 induce type II spectra, and all contain groups that can ligate
ferric heme iron through nitrogen atoms (e.g. imidazole, aro-
matic amine, and quinolone groups), with CYP126A1Kd values
from4 to 16M (Table 2). These compounds all induce heme
spectral shifts similar to those seen with the imidazole antifun-
gal drugs (Fig. 4).
EPR Spectroscopy of CYP126A1 and Ligand-bound Forms—
X-band EPR spectroscopy was used to analyze the heme iron
coordination environment of ferric CYP126A1 in its ligand-
free state and when in complex with (i) HTS type I compounds
1–6 and (ii) HTS type II compounds 7–9, as well as with a
group of small compounds (compounds 10–13) that were
identified to bind with modest affinity (150–550 M Kd) to
the CYP126A1 heme iron through amine, pyridine, or pyrazole
nitrogens. Ligand-free CYP126A1 has a rhombic LS spectrum
with a single major species, with g-values at 2.41 (gz), 2.24 (gy),
and 1.92 (gx), consistent with one dominant coordination state
from cysteine thiolate (proximal) and water (distal) ligands.
These g-values are similar to those reported for otherM. tuber-
culosis P450s, such as CYP125A1 (2.40/2.25/1.94), CYP142A1
(2.40/2.23/1.92), and CYP51B1 (2.44/2.25/1.91) (7, 8, 14).
EPR spectra for CYP126A1 in complex with compounds
1–13 revealed substantial perturbations in several cases that
were consistent with changes in distal heme iron coordination.
HTS type II compounds 7–9 produced new LS EPR spectra
consistent with distal ligation of CYP126A1 heme iron by a
nitrogen atom. Similarly, the binding of HTS type I molecules
resulted in new spectral signals indicative of the development of
HS ferric heme iron as well as inducing some perturbations to
the LS ferric signals. Selected EPR spectra are shown in Fig. 5.
CYP126A1 heme coordination by the four small nitrogen-
containingmolecules gave newLS spectrawith g-values at 2.44/
2.24./1.92 for 6-phenoxypyridin-3-amine (compound 10);
2.47/2.25/1.90 for 3-(pyridin-3-yl)propanoic acid (compound
11); 2.50/2.24/1.91 (minor) and 2.44/2.24/1.91 (major) for
4-(1H-pyrazol-1-yl)aniline (compound 12); and 2.48/2.25/1.89
for (4-(pyridin-4-yl)phenyl)methanol (compound 13). These
EPR data suggest that direct coordination of heme iron may
occur mainly through primary amine nitrogens in compound
10 and in the minor species in compound 12 (both with gz 
2.44). For the major species in compound 12 (gz  2.50), pyr-
azole nitrogen may be the ferric iron ligand. The similar EPR
spectral features for the CYP126A1 complexes with com-
pounds 11 and 13 (gz 2.47 and 2.48, respectively) suggest that
pyridine nitrogen ligates heme iron in both of these complexes
(Fig. 5A).
The type II hits fromHTS studies also perturbed the LS ferric
CYP126A1EPR spectra, producing new specieswith g-values at
2.49/2.24/1.88 (compound 7); 2.44/2.24/1.90 (compound 8);
and 2.46/2.25/1.90 (compound 9) (Fig. 5A). The magnitude of
change in the g-values for compounds 7–9 suggests heme coor-
dination through the imidazole, aniline, and pyridine nitrogen
atoms, respectively. For the type I HTS compounds, the devel-
opment of HS ferric heme iron spectra was observed for com-
pound 1 (gz 7.92, gy 3.57, gx 1.69) and to a smaller extent
for compounds 2 (7.79/3.77), 3 (7.85/3.63), and 4 (7.92/3.60).
For compounds 2–4, the HS gx signal was too small to be accu-
rately assigned. No significant EPR spectral changes were seen
for complexes with compounds 5 and 6. EPR spectra for
CYP126A1 complexeswith compounds1,2, and4 are shown in
Fig. 5B. The relatively small accumulation of a HS EPR signal
(compared with data collected by UV-visible titrations at ambi-
ent temperature) for many of the type I HTS compounds is
consistent with data for several other P450s on binding sub-
strate-like compounds and is probably due to the requirement
for collection of heme EPR spectral data at 10 K (32). A P450 in
which a much larger HS EPR signal is seen in the substrate-
bound form is the alkene producing fatty acid decarboxylase
OleT from a Jeotgalicoccus sp. OleT is converted to95% ferric
HS on binding arachidic acid (C20:0) and retains a large HS
TABLE 1
Binding constants for azole drugs with CYP126A1 and otherM. tuberculosis cytochrome P450 enzymes
The dissociation constants (Kd values) for the binding of imidazole and several azole drugs to CYP126A1 and to various otherM. tuberculosis cytochrome P450 enzymes
were determined by UV-visible absorbance titration. Data for ligand binding are taken from the following references: CYP126A1 (this work), CYP144A1 (31, 72), CYP125A
(7), CYP142A1 (8), CYP121A1 (19, 20), CYP130A1 (63), andCYP51B1 (14, 73). NB, no significant P450 spectral perturbationwas observed upon the addition of the relevant
azole drug. ND, there are no published data for the interaction of the relevant azole drug with the indicated P450 enzyme.
Azole inhibitor
Kd for P450-azole drug binding
CYP126A1 CYP144A1 CYP125A1 CYP142A1 CYP121A1 CYP130A1 CYP51B1
M
Econazole 4.0 0.6 0.78 0.29 11.7 0.7 4.6 0.2 0.024 0.006 1.93 0.03 0.31 0.04
Clotrimazole 3.9 0.4 0.37 0.08 5.3 0.6 3.8 0.9 0.073 0.008 13.3 0.6 0.18 0.02
Miconazole 1.3 0.2 0.98 0.22 4.6 0.4 4.0 0.5 0.136 0.021 1.70 0.21 0.20 0.04
Ketoconazole 0.34 0.07 134 5 27.1 0.9 21 4 3.41 0.31 48.0 1.5 3.57 0.25
Fluconazole NB 10,000 43.2 0.8 860 108 8.61 0.21 ND 5.82 0.12
Voriconazole NB 6510 450 NB NB 16.3 2.1 ND 2.10 0.16
4-Phenylimidazole NB 280 18 216 5 12.0 1.5 32.3 2.2 ND 452 27
Imidazole 2590 60 2965 275 536 7 ND ND ND 11700 900
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signal in the EPR spectrum, probably due to the presence of a
rigid binding site for the fatty acid carboxylate close to the heme
iron, leading to effective displacement of the water distal ligand
from the OleT heme iron (32). For the HTS compounds that did
induce formationof aHS ferric hemeEPR signal, therewas also an
effect on the LS spectrum.As seen in Fig. 5B, there are shifts in the
LS g-values to 2.38/2.22/1.96 (major), 1.92 (minor) for compound
1; 2.40/2.23/1.92 (major), 1.96 (minor) for compound 2; and 2.39/
2.22/1.96 (major), 1.92 (minor) for compound 4.
MagneticCircularDichroism(MCD)SpectroscopyofCYP126A1—
MCD spectroscopy was used as a complementary method to
EPR to probe electronic structure of CYP126A1. MCD data
were collected in both the UV-visible (250–800 nm) and
near-IR (800–1400 nm) regions. MCD features at different
wavelengths in the UV-visible and near-IR regions can be used
to probe heme structure and heme iron coordination (33, 34).
UV-visible MCD spectra can be diagnostic for the spin and
oxidation states of metal ions, and in heme proteins, the posi-
tions of the porphyrin macrocycle absorption bands are influ-
enced by the heme iron. Porphyrin-to-* transitions give rise
to MCD absorption features in the300–600 nm region, and
the mixing of the porphyrin- and iron-d electronic levels
enables UV-visible MCD to provide data on heme iron oxida-
tion and spin state (35). Fig. 6A shows the UV-visible MCD
spectrum of CYP126A1. The sharp feature at 292 nm is due
primarily to contributions from tryptophan residues. Other
major features in the heme spectrum (values in units of mM1
cm1) are located at 359 nm (43.4) and 407.5 nm (148.8),
with a crossover at 418.5 nm in the Soret region, and at 520 nm
(48.7), 556.5 nm (56.5), 546.5 nm (0), and 575.5 nm (83.8)
in the heme Q-band region. These features in the CYP126A1
UV-visible MCD spectrum resemble those of proteins with LS
ferric hemes. For example, the UV-visible MCD spectrum of
CYP126A1 is highly similar to that reported for the M. tuber-
culosis cyclodipeptide oxidase CYP121A1. Aminor trough fea-
ture at655 nm in the CYP126A1 UV-visible MCD spectrum
indicates a very small proportion of HS ferric cysteine thiolate-
coordinated heme iron (36).
A CYP126A1 MCD spectrum was also collected in the
near-IR region, to report on the position of a ligand-to-metal
CT transition that can be characteristic for the heme iron liga-
tion state in the ferric form (Fig. 6B) (34). The CYP126A1 CT-
band is located at 1097 nm. This position is consistent with
those seen in other P450 enzymes (e.g. the fatty acid/fatty
acyl-ACP oxidizing P450 BioI (CYP107H1) at 1090 nm and
CYP121A1 at 1125 nm) (36, 37).
Determination of the Heme Iron Reduction Potentials of Sub-
strate-free and Ligand-bound Forms of CYP126A1—The sub-
strate-free formofCYP126A1 is predominantly LS in its resting
ferric state. However, the binding of the type I HTS compounds
1–6 results in shifts towardHS heme iron, consistent with sub-
strate-like properties. In many bacterial P450s, the substrate-
induced HS shift is associated with a substantial increase in the
P450 heme iron FeIII/FeII reduction potential (e.g. from368 to
239 mV (versus normal hydrogen electrode (NHE)) for the
Bacillus megaterium CYP102A1 (P450 BM3) heme domain on
binding arachidonic acid and from approximately 300 to
170 mV for the Pseudomonas putida P450cam on binding
D-camphor) (38, 39).
To analyze the influence of type I compound binding to
CYP126A1, the heme iron redox potentials were determined
for both the substrate-free CYP126A1 and the CYP126A1-
compound 1 complex. The spectroelectrochemical redox titra-
tion for substrate-free CYP126A1 displays a Soret band transi-
tion from the oxidized form at 418.5 nm to a broad feature of
lower intensity, centered at 409 nm, as the heme iron is
reduced by progressive additions of sodiumdithionite (Fig. 7A).
FIGURE 3. Binding of the azole inhibitor ketoconazole and HTS com-
pound 1 to CYP126A1. A, a CYP126A1 (4.5 M) titration with the azole drug
ketoconazole. Ketoconazole coordinates the P450 ferric heme iron and
induces a type II red shift of the heme Soret band from 418.5 to424 nm at
near saturation. Isosbestic points are located at373, 502, and 549 nm. The
inset shows a plot of the maximal ketoconazole-induced heme absorption
change (	A433	A414) versus ligand concentration, with data fitted using a
tightly binding (Morrison) quadratic function to give a Kd of 0.34  0.07 M
(65). In both panels, arrows indicate directions of heme absorbance change at
different wavelengths during the progression of the titrations. Structures of
these molecules and other CYP126A1 ligands identified in this study are
shown in Fig. 4. B, a UV-visible absorbance titration of CYP126A1 (4.6M)with
compound 1 (N-isopropyl-N-((3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)
methyl)-2-(4-nitrophenyl)acetamide). Compound 1 induces a P450 sub-
strate-like type I blue shift of thehemeSoretband from418.5nm (ligand-free)
to 396 nm (nearly saturated with compound 1). Isosbestic points in the titra-
tion are located at 405, 462, and 524 nm. The inset shows a plot of the
maximal compound 1-induced heme absorption change (	A388  	A419)
versus ligand concentration, with data fitted using a hyperbolic (Michaelis-
Menten) function to give a Kd of 18.3 1.3 M.
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There are clear isosbestic points in the titration (at 410 and
437 nm), indicating a simple conversion between the oxidized
and reduced states without accumulation of an intermediate
species. By comparison with other P450s, the blue shift of the
Soret band and the spectral fusion of the - and -bands into a
singleQ-band feature at 550 nm is consistentwith the retention
of cysteine thiolate coordination in the ferrous heme iron form
(40, 41). A plot of absorbance at 402 nm versus applied potential
was fitted using the Nernst equation to give a midpoint poten-
tial for the CYP126A1 heme FeIII/FeII transition of 332  4
mV versus NHE (Fig. 7A, inset).
In the case of theCYP126A1-compound 1 complex, the P450
is extensively HS in the ferric state, with a Soret maximum at
FIGURE 4. Inhibitors and substrate-like ligands for CYP126A1. Several ligands and potential substrates for CYP126A1 were identified using HTS methods.
The figure shows (i) imidazole and imidazole-based azole drug inhibitors that coordinate the CYP126A1 heme iron, (ii) compounds identified by HTS that
induce type I (compounds 1–6, inducing HS heme iron accumulation) or type II (compounds 7–9, coordinating the P450 heme iron) spectral shifts, and (iii)
small nitrogen-containing molecules (compounds 10–13).
TABLE 2
Binding constants for compounds identified to bind CYP126A1
through high throughput screening studies
The dissociation constants (Kd values) were determined by UV-visible absor-
bance titration. HTS compounds 1–6 induce type I (accumulation of HS heme
iron) spectral shifts, whereas HTS compounds 7–9 reinforce the LS state of
CYP126A1 through distal coordination of the heme iron via a nitrogen ligand in
each case.
Type I Kd Type II Kd
M M
Compound 1 18.3 1.3 Compound 7 4.13 0.61
Compound 2 2.85 0.15 Compound 8 11.0 0.6
Compound 3 56.1 2.2 Compound 9 16.4 0.7
Compound 4 65.2 6.6
Compound 5 6.15 0.31
Compound 6 25.3 0.5
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394 nm and a cysteine thiolate-to-ferric heme CT signal at 647
nm. The reduction of the heme iron occurs with a Soret band
shift to 421 nmandwith loss of theCT and spectral bleaching in
the Q-band region. Isosbestic points in the redox titration at
406.5, 479, and 521 nm are again consistent with a simple two-
state transition between oxidized and reduced forms of the
CYP126A1-compound 1 complex (Fig. 7B). A plot of absor-
bance at 393 nm versus applied potential was again fitted using
theNernst equation, giving a hemeFeIII/FeIImidpoint potential
of 177  3 mV versus NHE (Fig. 7B, inset). Thus, binding of
compound 1 results in a 155-mV increase in the CYP126A1
midpoint potential, consistent with heme iron reduction being
favored in a substrate-bound form of the P450 (42).
Analysis of CYP126A1-mediated Oxidation of HTS Molecules—
Studies to identify products of oxidation from several of the
type I HTS compounds were done using two bacterial type
NADPH-dependent redox systems comprising (i) E. coli flavo-
doxin reductase and (ii) E. coli flavodoxin or spinach ferre-
doxin.No turnoverwas detectedwith compounds 1 and 2, both
ofwhich contain nitroaromatic groups. As discussed below, it is
likely that these compounds act as inhibitors of CYP126A1
while simultaneously inducing a type I CYP126A1 heme spec-
tral shift that is characteristic of substrate binding inmost other
P450s. Although evidence for oxygen incorporation (16 addi-
tion to the parent speciesmolecularmass) into aminor propor-
tion of compounds 3 and 6 could be obtained from the small
amounts of products resolved using LC-MS, there were insuf-
ficient products to identify the positions of oxidation. Extensive
turnover of compound 5 did not produce any significant
amount of oxidized product.However, in the case of compound
4 (3-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)-1-(4-
chlorobenzyl)pyrrolidine-2,5-dione), a greater amount of
oxidized product was formed. Although the precise position of
oxidation could not be resolved fully by molecular fragmenta-
tion, it was clear that oxygen addition (hydroxylation) occurs
on the 1,3-benzodioxole portion of the molecule (Fig. 8).
Analysis of CYP126A1 Oligomerization State and Ligand
Binding Stoichiometry by Nano-ESI-MS—In previous studies,
we used nano-ESI-MS to probe the oligomerization state of the
M. tuberculosis P450 CYP121A1 and the enzyme’s binding
interactions with azole drugs. These studies revealed that
ligand-free CYP121A1 is predominantly dimeric and that
tightly binding azoles cause dissociation of the P450 dimer. In
contrast, binding of the CYP121A1 substrate cYY gave a stable
species that did not undergo gas phase dissociation (43).
To assess the effect of ligand binding on CYP126A1 oligo-
merization state and to determine the stoichiometry of
CYP126A1-ligand binding interactions, a series of nano-ESI
native mass spectra were collected for CYP126A1 bound to the
azole compounds ketoconazole, econazole, and miconazole
and the HTS compounds 1, 3, 4, 5, and 7. The effect of organic
solvent on the ionization of CYP126A1 was first assessed. Low
concentrations of DMSO-d6 (2.5%, v/v) caused an expected
decrease in the charge state of the protein, shifting peaks for the
CYP126A1monomer fromm/z 3200–4200 tom/z 4000–5100,
but did not otherwise affect the quality of the spectra or the
oligomerization state of the protein (Fig. 9) (44, 45). Ligand-
bound spectra were collected at a minimum of three different
ligand/protein ratios (from 0.5:1 to 25:1), depending on the Kd
values of the respective ligand. The stoichiometry of ligand
binding was determined from the difference in the masses of
peaks corresponding to ligand-bound CYP126A1 and ligand-
free CYP126A1, divided by themolecular weight of the ligands.
Ketoconazole and HTS compounds 1, 3, and 7 all exhibited
clear binding at substoichiometric ligand/protein ratios (0.5:1)
(Table 3). In contrast, econazole, miconazole, and compound 5
did not achieve complete occupancy of the CYP126A1 mono-
mer until superstoichiometric ligand/protein ratios (5:1).
FIGURE 5. EPR spectra of CYP126A1. A, EPR spectra for CYP126A1 in its ligand-free form and for complexes with HTS compounds (compounds 7 and 9) and
other smallmolecules that ligateCYP126A1heme ironvianitrogen ligands (compounds11–13).B, EPR spectra forHTShits (compounds1,2, and4) that induce
HS heme iron accumulation in CYP126A1. The g-values for the LS and HS forms of CYP126A1 are indicated in each case.
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These differences in the relative concentration of bound and
unbound protein species observed in nano-ESI spectra are
influenced by the binding affinity of the ligand, exposure of the
binding site, and the type of intermolecular forces contributing
to binding interactions, among other factors (46–48). Dissoci-
ation constants determined using ESI mass spectrometry have
previously been reported to correlate reasonably well with Kd
values determined using other biophysical techniques for series
of structurally similar ligands (46, 49–51). A greater proportion
of ligand-bound CYP126A1 was observed at stoichiometric
(1:1) ligand/protein ratios for ketoconazole and compounds 1,
3, and 7 compared with the other HTS and azole compounds.
Because the solution phase Kd values of the CYP126A1 ligands
studied are all comparable, the differences in their gas phase
affinity most likely reflect the nature of their binding interac-
tions to the protein. Ligands whose binding affinity is predom-
inantly driven by hydrophobic interactions show weaker than
expected interactions in the gas phase, compared with com-
pounds with polar or ionic binding contributions (46). The
formation of ligand-protein complexes at substoichiometric
ligand/protein ratios for ketoconazole and compounds1,3, and
7 indicates strong gas phase binding. This is consistent with the
metal binding and hydrogen bonding interactions of these
ligands with CYP126A1 that are observed by X-ray crystallog-
raphy. In contrast, the azole drugs miconazole and econazole
had disproportionately weaker affinity in nano-ESI experi-
ments compared with their solution phase Kd values, which is
consistent with a hydrophobic mode of binding. The majority
of compounds showed a maximum 1:1 binding stoichiometry
over the concentration range tested. However, two of the HTS
FIGURE 6. MCD analysis of CYP126A1. The MCD spectra for CYP126A1 are
shown in the UV-visible region (A) and in the near-IR region (B). Spectra were
collected at room temperature using a CYP126A1 concentration of 200 M.
Spectral features are consistentwith apredominantly LS ferric heme ironwith
cysteine thiolate coordination.
FIGURE 7.Determination of the heme reduction potentials of ligand-free
and compound 1-bound CYP126A1. A, the main panel shows UV-visible
absorbance spectral data from a spectroelectrochemical redox titration of
ligand-freeCYP126A1 in thepotential range from170 to395mV (versus
theNHE). TheUV-visible Soret spectralmaximumshifts from418.5nmtoward
409 nm as the reductive titration approaches completion. In the Q-band
region, the - and -bands appear at 568 and 539 nm in the oxidized
enzyme, with the reduced CYP126A1 exhibiting a single absorption band at
550 nm. The absorbance versuspotential data at 402 nmwere fitted using the
Nernst equation to give a midpoint potential for the heme iron FeIII/FeII cou-
ple of332 4mV versusNHE (inset). B, a similar data set for the compound
1-bound form of CYP126A1. In this case, themain panel shows P450 spectral
data collected in the potential range from30 to265 mV versus NHE. In
the ferric state, the compound 1-bound CYP126A1 has a Soret maximum at
394 nm, with Q-band maxima at 538 and 568 nm, and with a low intensity
CT-band at647 nm. The reduced formhas a Soret spectralmaximumat 421
nm, with loss of absorbance intensity in the Q-band region and for the CT
species. Absorbance versus potential data were plotted at 393 nm and fitted
using the Nernst equation to give a heme ironmidpoint potential of177
3 mV versus NHE.
Novel Structural Properties of M. tuberculosis CYP126A1
JANUARY 27, 2017•VOLUME 292•NUMBER 4 JOURNAL OF BIOLOGICAL CHEMISTRY 1317
molecules (compounds 1 and 3) were calculated to bind twice
per CYP126A1 monomer at 5:1 ligand/protein ratios. No
change in the oligomerization state of CYP126A1was observed
with any of the ligands.
Crystal Structure of CYP126A1 in the Imidazole-bound
Form—The structure of the ligand-free form of CYP126A1
(PDB code 5LIE) was determined by molecular replacement
using the structure of the P450 EryF (CYP107A1), a 6-deoxy-
erythronlide B hydroxylase from the erythromycin biosynthesis
pathway in Saccharopolyspora erythraea (PDB code 1OXA)
(52). The CYP126A1 structure exhibits the characteristic P450
fold, and the ligand-free structure contains a dimer in the asym-
metric unit (Fig. 10). The dimer interface is made by the BC-
and FG-loop regions, both of which are associated with sub-
strate entry into P450 enzymes. Onemonomer (chain A) forms
a “closed” state with a relatively solvent-inaccessible active site
and has water as the sixth heme ligand. The other monomer is
bound to imidazole as the sixth heme ligand (probably retained
after the nickel affinity purification step in a proportion of the
P450 molecules). In contrast to the ligand-free active site, the
imidazole-bound form (chain B) contains a clear solvent access
channel (the “open” state). The access channel to the bound
imidazole is opened due to disorder of the FG-loop region (res-
idues 177–194). In comparison, the FG-loop region of chain A
is ordered but explores, in part, the chain B active site region.
Hence, it is possible that ligand binding to chain B affects the
conformation of chain A. An overlay of bothmonomers reveals
that imidazole binding is linked to a reorientation of the N-ter-
minal region of the I-helix at residues 240–257, moving Ala-
253 by 2.7 Å to avoid severe steric clashes with the heme sixth
ligand. Because the F- and G-helices are involved in hydropho-
bic contactswith this particular region of the I-helix, this I-helix
relocation leads to an accompanying shift in orientation of the
FG region. Whereas the chain B FG-loop is disordered, the
chain A FG-loop chain region makes contact with the chain B
I-helix N-terminal region at residues 194–196.
The asymmetric behavior of the CYP126A1 dimer can be
rationalized by the fact that a putative A-A symmetric dimer
(where both chains adopt the chain A conformation) is not
possible due to a severe steric clash of the respective FG-loop
regions. In other words, the ordered FG-loop region in chain A
at the dimer interface obscures the putative FG-loop docking
region for chain B. Because imidazole binding leads to reorien-
tation of the I-helix and consequently the FG-helix, it is possible
that imidazole binding to one monomer leads to the active site
closure of the second monomer. It is interesting to note that a
putative B-B symmetric dimer (where both chains adopt the
“open” chain B conformation) also appears possible.
Given the flexibility of the P450 fold, it is difficult to predict
substrate identity from P450 structures. In the case of
CYP126A1, the ligand binding pocket is not exclusively lined by
hydrophobic residues (Met-190, Leu-249, andAla-253) but also
contains Thr-83, Asn-96, Ser-300, Lys-303, Arg-400, and His-
401, suggesting that the physiological substrate probably exhib-
its hydrophilic properties. For chain B, the imidazole ligand is
positioned between I-helix residues Leu-249 and Thr-257 and
is stacked against Ala-253. In this case, the side chain of Arg-
400 has reoriented and points away from the active site.
Crystal Structure of CYP126A1 in Complex with Inhibitor
and Substrate-like Molecules—To further establish the nature
of CYP126A1 protein-ligand interactions and the effects these
have on protein oligomerization/conformation, we determined
the crystal structures of three distinct inhibitor complexes
through co-crystallization. Fig. 11 shows the binding modes
of ketoconazole (PDB code 5LI8), the smaller imidazole-
containing compound 7 (PDB code 5LI7), and compound 1
(PDB code 5LI6) in the active site of CYP126A1. These images
show that compounds 1 and 7 bind in a channel that follows the
general direction of the P450 I-helix. However, ketoconazole
binds in a different manner and extends from the heme in an
orthogonal direction to the other two molecules. The distinc-
tive binding mode for ketoconazole has ramifications for the
structural organization of CYP126A1.
The crystal structure of CYP126A1 in complexwith the azole
drug ketoconazole revealed that a large scale reorientation of
the BC-loop region has occurred in response to ligand binding,
disrupting the putative dimer interface observed in the imidaz-
ole-bound form (Fig. 12). Furthermore, the N-terminal region
of the I-helix and the associated FG-helices display compara-
tively more modest reorientations as a consequence of ligand
binding. The ketoconazole dichlorobenzene moiety occupies
the region previously filled by Leu-249, whereas the extended
FIGURE8.CYP126A1-dependentoxidationof compound4.A, LCextracted
ion chromatogram of CYP126A1 extracts following enzymatic incubations
with compound 4. Major peaks with retention times (rt) at 2.791 and 3.231
min are observed,withminor species at 2.916, 3.074, and 3.912min. The peak
at 2.791min (shaded in gray) corresponds to the (16) hydroxylation of com-
pound 4. B, mass spectrum following LC separation of the extracted major
product at 3.231 min, with m/z 442.1528 (M H) diagnostic of the parent
substrate ion of compound 4 ((C23H24ClN3O4) H)
 and a smaller species
withm/z 464.1348 for the compound 4 sodium ion adduct. C, mass spectrum
of the extracted 2.791-min peak showing the (16) hydroxylation of com-
pound 4 with m/z 458.1477 ((C23H24ClN3O5) H). Inset, amplification of the
peakm/z 458.1477, showing the ionization pattern for the hydroxylated form
of compound 4.
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tail of the molecule displaces the BC-loop residues Val-84 and
Leu-85, resulting in their forming hydrophobic contacts with
the FG-helices.
In contrast, the binding of the smaller imidazole-containing
compound 7 does not lead to BC-loop reorientation, and a
putative CYP126A1 dimer in complex with compound 7 in
both of its active sites is observed in the asymmetric unit. The
overall conformation is similar to the proposed B-B symmetric
dimer, with both chains adopting a conformation resembling
the imidazole-boundmonomer. In addition to heme iron coor-
dination by the compound 7 imidazole group, further contacts
with CYP126A1 are limited to hydrogen bonds with Asn-96
and Ser-252 and with the ligand urea moiety, whereas the ada-
mantyl group remains largely solvent-exposed (Fig. 12).
Unlike the previous ligands, compound 1 does not contain an
azole ring and instead elicits a type I heme shift suggestive of
substrate-like ligand binding. The crystal structure of CYP126A1
in complex with compound 1 reveals that the ligand is bound
with the nitrobenzenemoiety placed directly above and parallel
to the heme porphyrin plane (Fig. 12). This effectively ensures
FIGURE 9. Nano-ESI native mass spectra of CYP126A1-ligand complexes. A, spectra from bottom to top: ligand-free CYP126A1 (10 M) and CYP126A1 (10
M) bound to compound 7, miconazole, econazole, and ketoconazole (each 10M). B, from bottom to top: ligand-free CYP126A1 (10M); CYP126A1 bound to
compounds 4, 1, and 3 (each at 10 M); and CYP126A1 bound to compound 5 (50 M). All samples contained 2.5% (v/v) DMSO-d6. Dashed lines A and Bmark
the m/z corresponding to the ligand-free enzyme and to CYP126A1 bound to one molecule of ligand, respectively. *, unbound and miconazole-bound
CYP126A1 were unresolved at a 1:1 L/P ratio. The mass of the detected species (B) corresponds to 50% ligand-bound CYP126A1.
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that the heme iron sixth ligand water is displaced, explaining
the observed spectroscopic effect with HS heme iron for-
mation. As observed for the azole-containing ligands, the bind-
ing of compound 1 elicits a shift in the N-terminal region of the
I-helix to accommodate the nitrobenzene moiety, accompa-
nied by the reorientation of the FG-helix region. As observed
for compound 7, the BC-loop region appears unperturbed by
compound 1 binding. However, the putative dimer interface
observed in the CYP126A1-compound 1 complex is distinct in
nature. Although still composed of interactions between the
FG- and BC-loop regions, the respective orientation of both
monomers is altered. Although compound7 occupies a binding
pocket similar in nature to that observed for compound 1, it
appears that small changes in the conformations of residues
lining the compound 7 binding pocket (Gln-86 and Arg-400)
lead to distinct packing interactions with the FG-helices of the
opposite dimer. Crystallographic data are presented in Table 4.
Discussion
Orthologs of theM. tuberculosis CYP126A1 gene are widely
distributed among both pathogenic (e.g. Mycobacterium ulcer-
ans Agy99, 80% amino acid sequence identity) and non-patho-
genic (e.g. M. smegmatis mc2155, 79% identity) mycobacteria.
This suggests an important conserved function in these organ-
isms. Related P450s are also found in other actinobacteria (e.g.
Streptomyces sp. Eco86, 43% identity) and also among the
myxobacteria (e.g. S. cellulosum So ce56, 42% identity; and Stig-
matella aurantiaca DW4/3-1, 41% identity), again suggesting
that a common function may be retained in diverse bacteria
(53). Phylogenetic studies indicate that CYP126A1 is most
closely related to CYP125A1, CYP142A1, and CYP124A1 from
M. tuberculosis H37Rv, all of which have been implicated in
host cholesterol metabolism (6–9, 54, 55). However, we could
find no evidence for cholesterol binding to CYP126A1 by UV-
visible spectral titration. Although there are relatively few data
available on CYP126A1 from transcriptomics and microarray
studies, the CYP126A1 gene is not essential for the in vitro
growth of the virulentM. tuberculosis H37Rv strain. However,
its importance in the infective state remains uncertain (56).
CYP126A1 protein is clearly produced in M. tuberculosis and
was identified in M. tuberculosis H37Rv cell lysates by mass
spectrometry. Itwas not identified in bacterial culture filtrate or
membrane fractions, consistent with it being a soluble, cytoso-
lic protein (57, 58). Moreover, a computational analysis of pre-
dicted M. tuberculosis target proteins and their druggability
ranks CYP126A1 (and other M. tuberculosis P450s) in the top
50 potential targets amongmore than 1500 candidateM. tuber-
culosis proteins (59).
To characterize in more detail the structural and biochemi-
cal properties of CYP126A1, we purified the P450 using an
E. coli expression system and demonstrated by mass spectrom-
etry that the protein was intact. Nano-ESI native mass spec-
trometry indicated that the enzyme is predominantly mono-
meric but has a propensity to formhigher dimeric, trimeric, and
tetrameric species at relatively low concentrations (Fig. 1). This
property probably underpins the formation of CYP126A1
dimer crystals (see below). UV-visible spectroscopy confirms
typical heme spectral features in CYP126A1. A slow collapse of
the P450 form of the CYP126A1 FeII-CO complex at 448.5 nm
to the P420 state at 423 nmoccurs, and this phenomenon is also
observed in otherM. tuberculosis P450s (8, 13, 14). On the basis
of previous studies, it is expected that the thiolate-coordinated
P450 state would be stabilized by the binding of its natural sub-
strate (8, 18). Supporting this conclusion, the stabilization of
the thiolate-coordinated ferrous form of CYP126A1 is evident
in the redox titration of the P450 bound to the type I screening
hit compound 1. The blue Soret shift seen on CYP126A1-com-
pound 1 heme iron reduction, along with spectral “fusion” of
the Q-bands, is characteristic of retention of thiolate coordina-
tion in the ferrous state, whereas a Soret red shift (e.g. to 423 nm
in the case of M. tuberculosis CYP51B1) with shifted - and
-band features is typical for cysteine thiol-coordinated ferrous
heme iron (14, 38). The redox titration also reveals an
155-mV increase in the reduction potential of the CYP126A1
heme iron FeIII/FeII couple, an effect probably dominated by
the extensive conversion of the CYP126A1 ferric heme iron to
the HS state (38, 39). However, the significant structural rear-
rangements accompanying the binding of compound 1 (Fig. 11)
also alter the CYP126A1 heme environment and are likely to
influence the heme redox potential.
CYP126A1 binds avidly to a number of azole drugs but shows
a clear preference for binding azole antifungal drugs with imid-
azole rather than triazole groups. Azole binding to CYP126A1
induces a red (type II) Soret band shift with a distinctive
decrease of Soret absorbance intensity (by 15–20%) as the
titrations progress to completion (Fig. 3). An interesting pat-
tern of azole drug selectivity among M. tuberculosis P450s
emerges from data presented in Table 1. First, it is clear that in
the case of CYP126A1, CYP144A1, and CYP121A1, the affinity
for the imidazole-containing azole drugs is markedly greater
than those for the triazole-containing drugs tested. Indeed, no
significant type II Soret shifts were observed for CYP126A1
with fluconazole, voriconazole, or itraconazole. The CYP144A1
Kd values for econazole, clotrimazole, and miconazole are sub-
micromolar, whereas those for the triazoles fluconazole and
voriconazole are 10 and 6.5 mM, respectively. CYP121A1
binds fluconazole and voriconazole more tightly (Kd values are
TABLE 3
Binding stoichiometry and relative affinity of HTS compounds for
CYP126A1 determined using nano-ESI native mass spectrometry
Shown is the approximate ligand/CYP126A1 protein (L/P) binding stoichiometry
for selected HTS hits (compounds 1, 3, 4, 5, and 7) and azole drugs (ketoconazole,
miconazole, and econazole) at 0.5:1, 1:1, and 5:1 L/P ratios. The final column shows
the percentage occupancy of the ligand at a 1:1 L/P molar ratio. Two molecules of
compounds 1 and 3 can bind to CYP126A1 at a 5:1 L/P ratio. ND, no ligand-bound
CYP126A1 complex was detected at the given L:P ratio, or spectra were only col-
lected at higher L/P ratios.
Ligand Mr
Ligand binding stoichiometry CYP126-ligand
complex (1:1)L/P 0.5:1 L/P 1:1 L/P 5:1
%
Ketoconazole 531.434 0.3 1 1 46
Miconazole 416.123 ND 0.5a 1 NDa
Econazole 381.681 ND 0.3 1 0
Compound 1 410.43 1 1 2 51
Compound 3 313.36 1 1 2 52
Compound 4 441.912 ND 1 1 35
Compound 5 391.892 ND ND 1 ND
Compound 7 302.422 0.2 1 1 63
a Unbound and miconazole-bound CYP126A1 were unresolved at a 1:1 L/P ratio.
The mass of the detected species corresponds to 50% ligand occupancy.
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FIGURE 10. The crystal structure of CYP126A1. A, stereoview of the CYP126A1 dimer structure with the N-terminal region of the I-helix as well
as the F- and G-helices and the BC-loop region, colored in blue for the imidazole-bound monomer and in cyan for the ligand-free monomer. B, a
cross-section of the CYP126A1 dimer through both heme groups, revealing that the imidazole-bound monomer has an open active site with
access to solvent, whereas the opposite monomer has a closed active site. Color coding is as in A. C, stereoview of an overlay of both active sites of the
CYP126A1 dimer. Key residues are shown in atom colored sticks, with blue carbons for the imidazole-bound monomer and cyan carbons for the
ligand-free monomer.
FIGURE 11. Active site structures of CYP126A1-ligand complexes. Detailed views of the active sites of CYP126A1 are shown from the structures of the
complexes with the type II inhibitors ketoconazole (A) and compound 7 (B), and the type I substrate mimic compound 1 (C). Key residues are shown in atom
colored sticks, with the mFo DFc omit electron density for the various ligands contoured at 3 . The N-terminal region of the I-helix is shown in a schematic.
Compounds 1 and 7 bind in a channel that follows the general direction of the I-helix, whereas ketoconazole extends away from the heme in an orthogonal
direction.
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8.61 and 16.3 M, respectively), but affinity remains 120–
680-fold weaker than for econazole and miconazole. However,
there is much less discrimination between the imidazoles and
triazoles in at least CYP51B1 and CYP125A1, although vori-
conazole does not bind the heme iron in CYP125A1. For
CYP51B1, the binding of fluconazole and voriconazole is quite
tight (Kd 5.82 and 2.10M, respectively) and only 12–32-fold
weaker than that for clotrimazole, the tightest binding imidaz-
ole drug. Ketoconazole displays similar affinity (Kd 3.57 M)
to the triazole drugs in CYP51B1. It is known that that
FIGURE 12. Structures of CYP126A1-ligand complexes.Overlays of the various CYP126A1-ligand complex structures are shown. A, stereoview of an overlay
of the CYP126A1 ligand complex structures together with the ligand-free monomer structure (in cyan). The ligand complexes are colored blue for imidazole,
yellow for compound 7, red for compound 1, and green for ketoconazole. Only those regions affected in conformation by ligand binding are in color. B,
stereoviewof anoverlay of the various CYP126A1-ligand complex active sites.Color coding is as inA. TheN-terminal regionof the I-helix is shown, revealing that
highly ligand-specific changes occur. These are transmitted through to the F- and G-helices that are in direct contact with this region.
TABLE 4
Data reduction and final structural refinement statistics for theM. tuberculosis H37Rv CYP126A1 and drug complexes
Values in parentheses are for the highest resolution shell. NA, not applicable.
Parameters CYP126A1
CYP126A1
ketoconazole
CYP126A1
compound 1
CYP126A1
compound 7
Data collection
Space group P212121 C2 P21 P212121
Cell dimensions
a, b, c (Å) 58.93, 70.05, 233.66, 118.23, 59.66, 69.84, 69.62, 59.66, 118.47, 59.25, 69.91, 226.14
, ,  (degrees) 90, 90, 120 90, 93.2, 90 90, 98.03, 90 90, 90, 90
Rmerge (%) 0.034 (0.423) 0.048 (0.666) 0.031 (0.842) 0.024 (0.829)
I/I 13.4 (1.7) 19.1 (2.2) 11.9 (1.8) 20.1 (2.6)
Completeness (%) 99.6 (99.0) 92.47 (59.1) 99.5 (96.8) 99.8 (100)
Redundancy 3.7 (3.9) 3.9 (3.3) 4.0 (3.4) 7.3 (5.4)
Refinement
Resolution (Å) 46.99–1.80 (1.86–1.80) 43.86–1.83 (1.88–1.83) 32.14–1.95 (1.99–1.95) 57.31–1.58 (1.62–1.58)
No. of reflections 90,448 (8427) 37,754 (1747) 66,993 (4759) 122,489 (8783)
Rwork/Rfree 16.62/20.30 (18.0/23.9) 15.7/19.6 (24.0/33.5) 18.88/24.2 (31.6/38.9) 0.169/20.34 (26.0/31.5)
No. of non-hydrogen atoms 7079 3594 6948 7064
Mean B factor (Å2)
Protein 24.6 17.6 21.2 20.1
Non-heme ligand 21.7 17.1 18.7 23.4
Solvent 34.8 24.7 31.3 32.9
Root mean square deviations
Bond lengths (Å) 0.016 0.025 0.022 0.027
Bond angles (degrees) 1.444 2.001 1.775 2.056
Ligand-iron coordination distance (Å) 2.25 2.0 NA 2.01
Dimer interface (Å2) 5830 NA 3990 4160
Ramachandran statistics (%)
Preferred region 96.1 96.7 96.6 95.7
Allowed region 3.4 3.0 3.1 4.0
Outliers 0.5 0.3 0.3 0.3
PDB code 5LIE 5LI8 5LI6 5LI7
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CYP51B1, CYP125A1, and CYP142A1 are all sterol-oxidizing
P450s in M. tuberculosis, whereas no such role has been
assigned to CYP126A1 or the other M. tuberculosis P450s in
Table 1. The binding of fluconazole and voriconazole to
CYP126A1 is not detectable, whereas at least fluconazole binds
each of three known sterol-metabolizingM. tuberculosis P450s
with good to moderate affinity. It can thus be speculated that,
despite apparent phylogenetic relationships between CYP126A1
and sterol-metabolizingM. tuberculosis P450s, CYP126A1 has
taken a distinct evolutionary path and that its role in pathogenic
and non-pathogenic mycobacteria (and other bacteria) may be
unrelated tometabolism of host or environmental sterols.With
regard to the effectiveness of the various azole drugs in inhibit-
ing mycobacterial growth, preceding studies (60) showed that
the triazoles fluconazole and itraconazole had no significant
effect onM. tuberculosis growth in vitro, whereas ketoconazole
had anMIC of 8–16 g/ml against the virulentM. tuberculosis
H37Rv strain. Our own studies confirmed the greater potency
of the imidazole-containing azole drugs, with fluconazole prov-
ing ineffective against M. tuberculosis H37Rv, whereas econa-
zole (8 g/ml), miconazole (8 g/ml), clotrimazole (11 g/ml),
and ketoconazole (16 g/ml) all showed goodMIC values (20).
Imidazole azole drug potency was even greater against the lab-
oratory strain M. smegmatis mc2155 in most cases, with MIC
values of0.1g/ml for econazole, 0.1g/ml for clotrimazole,
and 1.25g/ml formiconazole, comparedwith100g/ml for
the triazole fluconazole (19). The enhanced azole potency
againstM. smegmatismc2155 may reflect greater drug perme-
ability as a consequence of altered glycolipid composition in the
cell envelope (61).
In work to identify novel type I and type II compounds bind-
ing to CYP126A1, we undertook a large (40,000) compound
screen and identified several molecules that induce CYP126A1
heme Soret shifts consistent with substrate-like (HS heme iron
accumulation with Soret blue shift) or heme iron-ligating
(Soret red shift, similar to that seen for azole drug binding)
properties. The compound hits selected for analysis were all
extended molecules containing between 2 and 6 aromatic or
non-aromatic ring structures (Fig. 4). Although these bulky
compounds do not provide immediate clues to the identity of
physiologically relevant substrates, type I CYP126A1 spectral
shifts were obtained in several cases, and evidence of P450-
mediated substrate oxidation of HTS type I compounds was
obtained in three cases, with the clearest results obtained with
compound 4.
Crystal structures were determined for CYP126A1 in the
absence of added ligand and for CYP126A1 in complex with
ketoconazole and with HTSmolecules compound 1 (type I hit)
and compound 7 (type II hit). The imidazole group of com-
pound 7 clearly ligates the heme iron, whereas the nitroben-
zene moiety of compound 1 is placed directly above the
heme plane and displaces the distal water, inducing adoption
of the HS ferric state in CYP126A1. No evidence of oxidation
of either compound 1 or compound 2 (which both possess a
terminal 4-nitrophenyl group) could be obtained in turnover
studies, and it thus appears that these molecules “moonlight”
as substrates but are not readily oxidized and instead act as
P450 inhibitors. A small number of nitroaromatic com-
pounds were identified as inhibitors of the P450-like, cys-
teine thiolate-coordinated nitric-oxide synthase enzymes
(62). However, there is no available evidence for their bind-
ing in a similar mode to that shown here structurally for
compound 1. The similar binding modes for both com-
pounds 1 and 2 to CYP126A1 suggest that binding studies
with other nitroaromatic compounds could identify more
potent inhibitors of CYP126A1.
The CYP126A1 structures reveal a dynamic molecule, with
the BC and FG regions clearly affected by ligand binding. These
regions are also involved in the formation of CYP126A1 dimers
observed in some crystal forms, as indicated by PISA analysis
(see Table 4 for corresponding dimer interface size), establish-
ing a putative link between ligand binding and protein oligo-
merization. However, it remains unclear whether the same
types of interactions lead to CYP126A1 dimerization in the
solution state. The malleable nature of CYP126A1 (as demon-
strated by its ability to bind to a range of structurally diverse
inhibitors and substrate-like molecules) suggests that the
nature of the physiological substrate does not necessarily reflect
the shape of the ligand-free CYP126A1 structure. However, the
nature of the residues that line the various active site regions
does suggest that the physiological substrate contains polar
moieties that might establish interactions with residues such
as Thr-83, Asn-96, Ser-300, Lys-303, Arg-400, and His-401.
Ketoconazole binding reorients the BC-loop region of
CYP126A1 and disrupts the dimer interface, resulting in a
binding mode for ketoconazole that is approximately
orthogonal to those for HTS compounds 1 and 7, which
extend upward from the heme, close to the path followed by
the I-helix (Fig. 11). The binding modes of these molecules
are compatible with CYP126A1 dimer formation in the crys-
tal, although differences in the dimer interface regions are
observed. The ability of CYP126A1 to form crystallographic
dimers is reminiscent of properties reported for the
M. tuberculosis CYP130A1 P450, with similar regions of the
P450s forming the dimer interfaces. However, whereas
CYP130A1 crystallizes as a monomer in the “open” confor-
mation when ligand-free, the econazole-bound form has a
“closed” conformation in a dimeric state (63). In contrast,
the ketoconazole-bound CYP126A1 is a crystallographic
monomer, whereas the ligand-free form of CYP126A1 is a
dimer containing both “open” and “closed” monomers.
In conclusion,we present the first biochemical and structural
studies of theM. tuberculosis P450 CYP126A1, revealing novel
substrates and inhibitors for the enzyme, defining its relatively
polar active site and its ability to adapt structurally to facilitate
the binding of bulky ligands. Future work will be directed at the
identification of the natural substrate(s) for this widely con-
served P450 enzyme.
Experimental Procedures
Cloning and Production of a CYP126A1 Expression Plasmid
Construct—The gene encoding CYP126A1 (Rv0778) from the
M. tuberculosis H37Rv strain was amplified by PCR from a
M. tuberculosis H37Rv chromosomal cosmid DNA library
(supplied by Dr. Roland Brosch, Institut Pasteur, Paris). The
CYP126A1-containing bacterial artificial chromosome clones
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were prepared using standard PCR amplification protocols
with Pfu Turbo DNA polymerase (Agilent, Cheadle, UK) used
to amplify the gene. The M. tuberculosis H37Rv genome
sequence was used to design primers to generate the Rv0778
gene for insertion into the pET15b plasmid vector using the
forward primer 5
-GCGGCAGCCATATGACTACCGCCG-
3
 and the reverse primer 5
-GCGCGGAGGCTAGGATC-
CGGCTGC-3
 (Merck-Millipore, Watford, UK). The under-
lined letters in the forward and reverse primers indicate
engineered NdeI and BamHI restriction endonuclease sites,
respectively. The boldface letters indicate the start (ATG) and
stop (TAG) codons, respectively. The gene amplification con-
ditions used were 95 °C for 2 min; 30 cycles of 95 °C for 45 s,
62 °C for 30 s, and 72 °C for 1.5 min; and then a final polymer-
ization step of 72 °C for 10 min. The PCR product was then
digested using NdeI/BamHI and cloned into pET15b using a
Quick Ligation Kit (New England Biolabs, Hitchin, UK) to gen-
erate the pCYP126A1 construct.
Expression and Purification of CYP126A1—The production
of CYP126A1 protein was achieved by transforming E. coli
strain BL21 Gold (DE3) (Agilent) or C41 (DE3) (Merck-Milli-
pore) with the pCYP126A1 plasmid construct. Gene expression
used an isopropyl -D-thiogalactopyranoside (IPTG)-inducible
T7 RNA polymerase/promoter system. IPTG-dependent
expression of the T7 RNA polymerase from a chromosomally
integrated gene copy in C41 (DE3) resulted in T7 RNA poly-
merase-dependent transcription of the CYP126A1 gene in
pET15b. Production of CYP126A1 protein was typically done
in 15-liter cultures of 2xYT growth medium (ForMedium,
Hunstanton, UK). The culture medium was distributed among
24 2-liter conical flasks, each containing 600 ml of growth
medium and ampicillin (50 g/ml) for plasmid selection. The
medium was inoculated with 6 ml of E. coli transformant cells
from an overnight culture of cells grown in the same medium.
The cells were grown at 37 °C with agitation (200 rpm) until an
A600 of 0.5 was reached, and then the growth temperature was
decreased to 23 °C, and bacterial cell growth continued until an
A600 of 0.7 was reached. 100M IPTGwas then added to induce
CYP126A1 gene expression, along with 100 M 	-aminole-
vulinic acid to promote heme synthesis and its incorporation
into the P450. The transformant cells were then grown for a
further 36 h under the same conditions. The cells were har-
vested by centrifugation at 6000 g for 10 min at 4 °C using
a JLA-8.100 rotor in an Avanti J-26 XP centrifuge, after
which the supernatant was discarded and cell pellets were
resuspended in 300 ml of ice-cold 50 mM potassium phos-
phate (KPi, pH 8.0) containing 250 mM NaCl and 10%
glycerol (buffer A). The protease inhibitors PMSF (1 mM),
benzamidine hydrochloride (1 mM), and six cOmpleteTM
EDTA-free tablets (Roche Diagnostics Ltd., West Sussex,
UK) were added to inhibit proteases. The cells were lysed on
ice by ultrasonication (Bandelin Sonopuls sonicator) with six
cycles of 30-s on and 60-s rest periods at 45% amplitude. The
cell lysate was then centrifuged at 40,000  g for 45 min at
4 °C, and the supernatant was collected.
After centrifugation, the supernatant was loaded immedi-
ately onto anNi-IDA column (Generon,Maidenhead, UK) pre-
equilibrated with cold buffer A plus the aforementioned prote-
ase inhibitors, using a peristaltic pump (GE Healthcare, Little
Chalfont, UK). The columnwas washed with100ml of buffer
A, and the flow-through was discarded. Proteins were eluted
from the columnbywashing consecutivelywith increasing con-
centrations of imidazole (30 mM (250 ml), 60 mM (150 ml), 120
mM (100 ml), and 180 mM (100 ml) in buffer A). Each eluted
fraction was analyzed both by UV-visible spectroscopy (250–
800 nm), and by SDS-PAGE. Fractions containing relatively
pureCYP126A1 (mainly the 80, 120, and 180mM samples) were
pooled and concentrated to100 ml using ultrafiltration with
Amicon concentrators (Merck-Millipore) at 4 °C. Thereafter,
concentrated protein was dialyzed into 50 mM Tris-HCl (pH
7.2, dialysis buffer) containing 50 mM KCl and 1 mM EDTA to
remove excess imidazole. The dialyzed protein was then loaded
onto a Q-Sepharose column (10 4 cm) pre-equilibrated with
the dialysis buffer, and the column was then washed and the
proteinwas elutedwith a linear gradient of KCl (50–500mM) in
dialysis buffer using an AKTA purification system (GE Health-
care). Fractions were analyzed by UV-visible spectroscopy and
by SDS-PAGE as before. Samples with high A418/A280 (or Rz)
ratios (	1) were pooled and concentrated to200 l by ultra-
filtration using a Centriprep 30 concentrator (Merck-Milli-
pore) at 1500  g. The concentrated protein was further dia-
lyzed into 10 mM Tris-HCl (pH 7.5) containing 150 mM NaCl.
The protein was then subjected to a final purification step using
Sephacryl S-200 size exclusion chromatography on an AKTA
purifier. Fractions were again analyzed both by UV-visible
spectroscopy and by SDS-PAGE. Fractions with Rz values of
	1.5 were seen to be pure by SDS-PAGE, and these were
pooled and concentrated as before and dialyzed into 50 mM
Tris-HCl, pH7.5, containing 50mMNaCl and 20%glycerol, and
stored at80 °C until use.
LC-MS Studies—Protein stock solutions (40 M) were pre-
pared by dilution of purified CYP126A1 protein (500 M) in
200 mM ammonium acetate buffer, pH 7.0. Samples were buf-
fer-exchanged by size exclusion chromatography using Micro
Biospin 6 columns, molecular weight cut-off 6000 (Bio-Rad,
Hemel Hempstead, UK). LC-MS was performed on a Xevo
G2-S QTof UPLC instrument (Waters, Elstree, UK) coupled to
an Acquity UPLC system. Samples were eluted through an
Acquity UPLC BEH300 C4 column (1.7 m, 2.1  50 mm)
using mobile phases of water with 0.1% (v/v) formic acid (Sol-
vent A) and 95% (v/v) acetonitrile in water, containing 0.01%
(v/v) formic acid (Solvent B). A solvent gradient of 95% Solvent
A for 5.21 min, 100% Solvent B for 1 min, and 100% Solvent A
for 1 min at a flow rate of 0.2 ml min1 over a total run time of
7.29 min was used to elute samples. The electrospray source
was operated with a capillary voltage of 2.0 kV and a cone volt-
age of 40 V. Nitrogen was used as the desolvation gas at a total
flow of 850 liters/h. Data acquisition and processing were per-
formed using Micromass MassLynx version 4.1 software with
total mass spectra reconstructed from the ion series using the
preinstalled MaxEnt algorithm.
Nano-ESI Mass Spectrometry—Protein stock solutions (20
M)were prepared as described above for LC-MS. Ligandswere
prepared as stock solutions in DMSO-d6 at 0.2–1 mM concen-
trations. Ligand-protein samples were prepared by diluting
protein (10 l) and ligand stocks (0.5 l) with ammonium ace-
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tate buffer (9.5 l) to give final concentrations of 10 M
CYP126A1, 5–250 M ligand, and 2.5% (v/v) DMSO-d6. Mass
spectra were recorded on a Synapt HDMS instrument (Waters
UK Ltd., Manchester, UK). Capillaries for nano-ESI MS were
purchased from ThermoFisher (Hemel Hempstead, UK). Cap-
illary tips were cut under a stereo microscope to give inner
diameters of 1–5 m and then loaded with 2.5 l of sample
solutions. Given below are the general instrumental conditions
used to acquire the reported spectra. However, the parameters
were varied over the course of each experiment to observe the
strength of protein-ligand complexes under different ionizing
strengths. All measurements were carried out in a positive ion
mode with an ion source temperature of 20 °C, a capillary
voltage of 1.5 kV, a cone voltage of 40 V, and an extraction
cone voltage of 4.8 V. All reported spectra were collected
with a trap collision energy 30–60 V, transfer collision
energy 12–30 V, IMS pressure 5.02  101 millibars, and
TOF analyzer pressure 1.17  101 millibars. External cali-
bration of the spectra was achieved using cesium iodide at
100 mg/ml in water. Data acquisition and processing were
performed usingMicromassMassLynx version 4.1. Mass dif-
ferences resulting from ligand binding were calculated from
the unbound protein peak internal to each spectrum. The
unbound protein peak was compared with the relevant 5%
(v/v) DMSO-d6 control spectrum for consistency. Mass dif-
ferences were divided by the molecular weight of the ligand
to calculate binding stoichiometry.
UV-visible Absorbance Titrations—Optical titrations to
determine Kd values were carried out on a Cary 60 UV-visible
spectrophotometer (Varian, UK) according to methods
described previously (64–67). All titrations were performed
using 1-cmpath length quartz cuvettes. For binding studies, the
following compounds were used: (i) azole antifungal drugs; (ii)
compound hits identified from a high throughput screen (these
compounds were identified on the basis of CYP126A1 heme
spectral perturbation using a library of 40,000 organic com-
pounds); and (iii) a group of small compounds able to bind
CYP126A1 heme iron through amine, pyridine, or pyrazole
nitrogens.
High throughput compound screening was performed at the
Screening Unit at the Leibniz-Institut für Molekulare Pharma-
kologie (FMP), Berlin, using a 40,000-compound library of
organic compounds. In brief, compound stock solutions were
prepared in DMSO at 10 mM. Medium throughput pipetting
robots (Sciclone 3000, Caliper Life Sciences, Hopkinton, MA)
were used to aliquot the library (0.4l) into 384-well microtiter
plates, and the compounds were diluted in 50 mM Tris-HCl, 50
mMTris-HCl pH 7.5 buffer (40l) containing 10% glycerol to a
concentration of 100 M. The plates were then incubated at
37 °C for 15 min, followed by 5 min of sonication to ensure
solubilization of the library compounds and then centrifuga-
tion for 10min to remove any particulate material. Absorbance
readings of the plates were done using a plate reader (Safire,
Tecan, Reading, UK) as a background value as well as for start-
ing reference spectra of the ligand-free CYP126A1 protein.
CYP126A1 (10l of 10M solution) was then pipetted into the
plates, and absorbance spectra were recorded between 350
and 460 nm to analyze compound-induced changes in the
CYP126A1 heme spectrum. Control data were also generated
during the screening process, including following the addition
of miconazole and clotrimazole as verified type II ligands for
CYP126A1. Background spectra of the compounds and refer-
ence spectra of ligand-free CYP126A1 were subtracted from
the spectra generated following the additions of the compound
librarymolecules to generate difference spectra.Measurements
at each wavelength were averaged and assigned scores based
upon the extent of changes in the difference spectra to deter-
mine hit compounds. 15 type I and 15 type II compounds were
identified as “hits,” and the top ranking compounds were pur-
chased, where available, from ChemDiv (San Diego, CA) or
Vitas M (Apeldoorn, The Netherlands).
Compounds were prepared as stock solutions (0.1–100 mM)
in DMSO and titrated (in 0.1–0.2-l aliquots) into 1-ml
cuvettes containing either a solution of CYP126A1 (typically
4–6 M) in 100 mM KPi (pH 7.0) plus 10 mM KCl (buffer B) or
buffer alone. DMSO concentrations did not exceed 1% of the
final assay volume, and the CYP126A1 absorbance spectrum
was not affected by DMSO within this range. Spectra were
recorded continuously between 800 and 250 nm at 25 °C.
Spectra collected from the buffer control cuvette were sub-
tracted from protein spectra to remove any optical interfer-
ence from small molecule absorbance. Difference spectra
were generated by subtraction of the initial ligand-free pro-
tein spectrum from each successive ligand-bound protein
spectrum. The maximum change in absorbance for each dif-
ference spectrum (	Apeak  	Atrough) was then plotted
against ligand concentration. Data were fitted using a stan-
dard hyperbolic (Michaelis-Menten) function or the Morri-
son equation for tightly binding ligands in cases where theKd
for the ligand was 
5 times the CYP126A1 concentration
used in the binding assay. The Hill function was used when
plots of induced absorbance change versus ligand concentra-
tion were clearly sigmoidal in character, as described in pre-
vious studies (64–67).
EPR andMCD Spectroscopy—X-band EPR spectra of ligand-
free CYP126A1 (200 M) as well as CYP126A1 (200 M) bound
to various ligands (typically 500 M) were recorded using a
Bruker ER-300D series electromagnet and a microwave source
interfaced with a Bruker EMX control unit, which was fitted
with an ESR-9 liquid helium flow cryostat (Oxford Instru-
ments) and a dual-mode microwave cavity from Bruker (ER-
4116DM). Spectra were recorded at a temperature of 10 K, a
microwave power of 2.08milliwatts, and an amplitude of 1 mil-
litesla. Samples were prepared in buffer B, with ligands added
from concentrated stock solutions in DMSO. MCD spectra
were collected for CYP126A1 in the near-UV-visible and
near-IR regions, using Jasco J-810 and J-730 circular dichro-
graphs, respectively, and using an Oxford Instruments super-
conducting solenoid with a 25-mm ambient bore to generate a
magnetic field of 6 teslas. A 0.1-cm path length quartz cuvette
was used to record near-IR spectra at a sample concentration of
200 M. UV-visible MCD spectra for CYP126A1 (also at 200
M) were recorded using a 0.2-cm path length quartz cuvette in
50mMpotassium phosphate in 2H2O (pH* 7.5) as buffer (where
pH* is the apparent pH measured in 2H2O using a standard
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glass pH electrode). Data analysis was done using Origin soft-
ware (OriginLab, Northampton, MA).
RedoxPotentiometry—Themidpointpotential for theCYP126A1
heme FeIII/FeII couple was determined for the substrate-free
CYP126A1 and for the P450 bound to a molecule identified
through high throughput screening to induce a substantial sub-
strate-like shift in CYP126A1 FeIII heme iron equilibrium
toward HS (compound 1, (N-isopropyl-3-(4-nitrophenyl)-N-
((3-N-(p-tolyl)-1,2,4-oxadiazol-5-hexyl)methyl)prop-1-en-2-
amine)). Spectroelectrochemical titrations were performed in
an anaerobic glove box (Belle Technology) under a nitrogen gas
atmosphere. All solutions were degassed under vacuum with
nitrogen before use in the glove box. Oxygen levels were main-
tained at 5 ppm. The concentrated CYP126A1 protein sam-
ples were passed through a Sephadex G25 column (1 20 cm)
(10DG column, Bio-Rad) immediately upon admission to the
glove box to remove traces of oxygen. This column was pre-
equilibrated, and proteins were buffer-exchanged into anaero-
bic 100 mM potassium phosphate, pH 7.0, plus 10% glycerol to
stabilize the protein from aggregation during the titration. The
CYP126A1 solutions (10–15 M enzyme in 5 ml of buffer)
were titrated electrochemically according to the method of
Dutton (68, 69), using sodium dithionite as reductant and
potassium ferricyanide as oxidant. For compound 1-bound
CYP126A1, the compound was added until no further induc-
tion of HS heme iron accumulation was observed. Mediators
were added to expedite electronic equilibration in the system
(2 M phenazine methosulfate, 5 M 2-hydroxy-1,4-naph-
thoquinone, 1 M methyl viologen, and 1 M benzyl violo-
gen) and to mediate in the range between approximately
100 and 480 mV versus the NHE (69). 10–15 min were
allowed to elapse between each addition of reductant/oxi-
dant to ensure equilibration and stabilization of the elec-
trode reading. Spectra (250–750 nm) were recorded using a
Cary UV-50 Bio UV-visible scanning spectrophotometer
coupled to a fiber optic probe immersed in the CYP126A1
solution. The potential was measured using a SevenEasy
S20-K meter (Mettler Toledo, Leicester, UK) coupled to a
Calomel electrode (ThermoRussell, Cupar, UK) at 25 °C.
The calibration of the electrode was done by using the FeIII/
FeII EDTA couple as a standard (108 mV). The electrode
reading was corrected by 244 mV relative to the NHE.
Absorbance data at wavelengths reporting on the transition
of the heme Soret band between oxidized (FeIII) and reduced
(FeII) forms of the CYP126A1 were plotted versus applied
potential, and the data were fitted using the Nernst function
in Origin version 8.0 (OriginLab).
Analysis of CYP126A1-dependent Oxidation of Substrate-
like Molecules from Compound Screening—CYP126A1 activity
assays with type I molecules fromHTS studies were carried out
with 0.5–1 M CYP126A1, 10–20 M spinach ferredoxin or
E. coli flavodoxin, 2.5 M E. coli flavodoxin reductase, and 10
M screening compound. Turnover reactions were performed
in total volumes of 1ml (or 5ml forMS fragmentation analysis)
in 50 mM KPi, 50 mM KCl, pH 7.0. Reactions were initiated by
the addition of 1 mM NADPH with a regenerating system (10
mM glucose 6-phosphate and 2 units of glucose-6-phosphate
dehydrogenase) and incubated at 30 °C for 30 min. Reactions
were terminated by the addition of 2–5ml of dichloromethane.
The organic phase was extracted twice following centrifuga-
tion, evaporated, and dissolved in 50:50 acetonitrile/methanol
for LC-MS studies. Samples were analyzed on an Agilent 6550
iFunnelQ-TOFLC-MSwith a 1290 Infinity LC system.AZOR-
BAX Eclipse Plus C18 (2.1 50mm; 1.8 m) Rapid Resolution
HT column (Agilent) was used with gradients of 0.1% formic
acid to acetonitrile or methanol to resolve products. Fragmen-
tation data analysis was performed with the MassHunter MSC
(Molecular Structure Correlator) program (Agilent).
Crystallography and CYP126A1 Structure Determination—
Crystals of native, ligand-free CYP126A1 were obtained by
mixing 1 l of 20 mg/ml P450 with 1 l of a reservoir solution
containing 38% (v/v) saturated sodium sulfate, 10% (v/v) 1 M
Tris-HCl (pH 6.5) and by incubating at 4 °C for 24–48 h. Before
data collection, the CYP126A1 crystals were soaked for 5–10 s
in a cryoprotectant solution consisting of mother liquor sup-
plemented with 10% polyethylene glycol 200. The imidazole-
ligated structure was solved to a resolution of 1.7 Å by molecu-
lar replacement using Phaser, giving a unique solution when
using PDB entry 1OXA as a startingmodel against data extend-
ing to a resolution of 2.8 Å (70). Refinement andmodel building
were carried out using ArpWarp, Phenix, and COOT (71). No
F/F restrictions were applied to the data during refinement,
and detailed data and final refinement statistics are given in
Table 4.
The crystal structure of the CYP126A1 complex with the
azole drug ketoconazole was obtained by co-crystallization.
CYP126A1 (20mg/ml) wasmixed with 2l of a saturated keto-
conazole solution. Sitting drops were prepared by mixing 1 l
of ketoconazole-bound CYP126A1 with 1 l of mother liquor
(40% saturated sodium sulfate, 0.1 M Tris, pH 7.0). These were
incubated at 4 °C and formed small needle-shaped crystals.
Streak seeding was then used to generate better quality, rod-
shaped crystals in 38% saturated sodium sulfate, 0.1 M sodium
cacodylate, pH 6.5. Crystals were soaked in cryoprotectant, as
above, and flash-cooled in liquid nitrogen for X-ray diffraction
experiments.
Crystals of other CYP126A1 complexes were also obtained
by co-crystallization after mixing CYP126A1 with these com-
pounds. The CYP126A1-compound 1 complex formed crystals
in 0.1 M carboxylic acids, 0.1 M imidazole-MES, pH 6.5, and 30%
ethylene glycol-PEG 8000. The CYP126A1-compound 7 com-
plex formed crystals in 0.2 M sodium sulfate, 0.1 M Tris pH 7.5
buffer, and 20% PEG 3350. Following data collection, refine-
ment andmodel buildingwere carried out usingArpWarp, Ref-
mac, andCoot (71). Detailed data and final refinement statistics
are given in Table 4.
Materials—Azole anti-fungal drugs were purchased from
MP Biomedicals Inc. Novel compounds (compounds 1–9)
were from the compound library of the Screening Facility at
the Department of Medicinal Chemistry, Leibniz Institute of
Molecular Pharmacology (Berlin, Germany) or sourced from
ChemDiv or Vitas M. Bacterial growth medium (2xYT) was
from Melford Laboratories (Ipswich, Suffolk, UK). Unless
otherwise mentioned, all other reagents were purchased from
Sigma-Aldrich and were of the highest grade available.
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